We are inspired by creating in vitro models that faithfully replicate in vivo immune cell interactions and have established an extensive portfolio of complex primary cell models that allow you to truly understand the therapeutic potential of your drug candidates, with benchmarked efficacy against best in class approved medicines.
Modelling immune cell interplay within an in vitro system is challenging yet critical to the true understanding of molecular mechanisms of actions and efficacy. Our data supports in vitro pharmacological assessment across therapeutic drug classes, including antibodies, immune cell engagers, cell therapies, immuno-metabolism and immune cell signalling modulators, immuno-cytokines, multi-specifics and beyond.
Whether your molecule is intended to reverse T cell exhaustion, suppress or incite effector function, activate regulatory T cells or optimise T cell killing, our immunology and bioassay design experts have created robust platforms employing a full range of T cell, NK cell, DC, monocyte and macrophage subtypes that can yield the mechanistic data you need from your drug candidates.
Let our immunologists propose the right system for your therapeutic, book a meeting with us today.
Access our cell line development expertise to accelerate your drug development pipeline, elucidate specific mechanisms of action and fine tune your molecule’s properties to enhance your overall data package. Our team has a track record of conceptualising, designing and crafting cell lines to the most exacting specifications and for the most challenging projects.
We’re able to achieve this through application of proprietary technologies, including rapid retargeting platforms and inducible expression systems, which are underpinned by an extensive back catalogue of ready-to-go reporter and target-engineered immortalised cell lines to deliver rapid solutions.
Whether you require expression of a large or challenging-to-express protein, desire attenuated, variable or specific levels of expression or simply need a synthetic construct to generate custom reporter cell systems, we have the solutions and can quickly deliver the right cell line for you.
Book a meeting to discuss how we can design and deliver the cell lines you need.
It is a regulatory requirement to fully characterise the effector function of antibody-based drugs. MoAs must be evidenced, while proving absence of effector function is equally important yet challenging to demonstrate convincingly. Our comprehensive packages provide full binding data and marry this with full characterisation of effector function.
Binding: Applying our unique Fcγ receptor SPR binding platform delivers exceptional assay performance across the full murine, cynomolgus and human Fcγ receptor and FcRn repertoires, supporting you to design and select antibody candidates with the optimal Fc binding characteristics from the earliest stages of development. Our methods go beyond simple presence or absence of binding to individual receptors with superior sensitivity, designed to detect small differences between molecules, benchmarking results against truly silenced or high binding controls.
Assay performance is enhanced through the use of high quality Fcγ receptors and FcRn, produced in house to quantities that allow our unique inverse orientation assay design, capturing test antibodies in the first step of the assay. Acting as a sample purification step, this eliminates non-specific binding of contaminants and reduces overall material requirements. Samples can be tested in high throughput formats with data rich reports including full kinetic analysis (KD, ka, kd) and sensorgrams.
Effector function: We apply primary cell or reporter cell methods to assess antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP). We specialise in implementing the appropriate assay design with built-in controls for the anticipated level of effector function to support data interpretation. Our primary cell assays are enhanced with use of characterised donors. Schedule a meeting today to explore our range of antibody characterisation platforms.
Increase the power of your primary cell studies by improving assay responsiveness, reliability and reproducibility by allowing us to assist in the design and performance of your next study.
Even the most basic assay formats employing primary cells suffer from donor variability. Storage and screening of ample material is costly and time-consuming. We alleviate these issues by providing our high-quality cellular material that has been functionally qualified in the assays that matter to you. This includes pre-screening of donors for effector functions, allogeneic responses in mixed lymphocyte reactions and antigen recall assays.
We stock thousands of cryovials of genotyped (CD16a, CD32a) human PBMCs on site, with up to 300 vials per batch, from recallable leukapheresis donors. This provides choice and repeat access with the option to reserve, allowing you to perform assays over many years using material from the same donor. Where whole or fresh blood donation is optimal, we provide access to a pool of volunteers, with corresponding genotype information available (CD16a and CD32a).
Custom characterisation is routinely conducted as part of donor selection to determine the relative percentages of immune cell types, allowing selection of those with desired characteristics or simply limiting the impact of donor-to-donor variation. We have established robust protocols that allow studies to be conducted using isolated and/or in vitro differentiated or expanded cell populations (full range of T cell, NK cell, DC, monocyte and macrophage cell types). Let’s discuss how our donor materials can enhance your studies today.
Leverage our experience of conducting analytical similarity studies from over 15 different biosimilar antibodies to accelerate the development of your next biosimilar program.
With a unique combination of immunology and bioanalytical expertise coupled with a deep understanding of the requirements for biosimilar analytical similarity assessments, we can comprehensively characterise the functional attributes of your biosimilar antibodies. Critical to these evaluations is the ability to not only control assay performance but deliver appropriate sensitivity to product attributes that influence functional outcomes whilst ensuring that test methods are conducted with biological relevance in mind. We deftly juggle these conflicting requirements and have created a unique range of platforms and capabilities, many of which are proprietary and unique to us.
These include a wide range of off-the-shelf assay formats, generic antibody characterisation platforms and custom assay development capabilities, performed using advanced instrumentation. Speak to one of our Biosimilar experts today.
The therapeutic efficacy of a biologic is rarely the outcome of a single mechanism of action and understanding the contribution of binding activity and functional modulation together with the knowledge of how the different components of a molecule interact with the immune system is essential to the design of an effective therapeutic. Accurate understanding of these relationships is also critical at the beginning of the drug discovery process and continues throughout the development life cycle as lead candidates are selected and optimised as production processes become established and refined.
Ultimately, this process delivers knowledge of the product’s critical quality attributes which are destined to become hardcoded within the specifications for product release. The combination of our ready to go solutions, platform approaches and custom development expertise provides you with the necessary resources to comprehensively define binding and biological activity from the start of your development journey in a cost and time effective manner.
We offer a myriad of solutions to measure recombinant and cell-based target binding, interrogate primary mechanisms of action to define pharmacological and biological activity and proprietary approaches to confirm the absence of effector function or sensitively define the level of activity using fully characterised and biologically relevant effector preparations.
Contact us today to expedite your drug discovery journey.